Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Sergio Fazio Added: 3 years ago
The wide utilization of anti-cholesterol agents, such as the statins, has created confusion among patients and clinicians about what to do when the lipid problem is one of triglycerides and high-density lipoprotein (HDL), rather than one of low density lipoprotein (LDL). Although most patients with diabetes have a dyslipidemia characterized by high triglycerides and low HDL (atherogenic… View more

Prevention & Chronic Conditions
Author(s): Sergio Fazio Added: 3 years ago
Current Indications for Statin and Fibrate Therapy The evidence of cardiovascular protection afforded by statins has recently extended beyond patients with hypercholesterolemia. With the publication of several trials,1-7 bold extrapolations of the power of statin therapy in cardiovascular prevention have been offered: statins equally reduce risk in subjects with or without… View more

Prevention & Chronic Conditions
ACC 2021: The VOYAGER PAD Trial
Author(s): Rupert Bauersachs Added: 2 years ago
Prof Rupert Bauersachs (Clinic Darmstadt, Darmstadt, DE) discusses the results from the VOYAGER PAD trial.The aim of the trial was to evaluate rivaroxaban/aspirin compared with placebo/aspirin among patients with lower extremity peripheral artery disease (PAD) undergoing revascularization. Questions What is the VOYAGER PAD Trial and what does it aim to address? What was the study design,… View more

Vascular Disease and Surgery

Intervention
AHA 2023 Late-Breaking Science Lineup Revealed
Added: 6 months ago Source:  AHA, Jordan Rance
The American Heart Association has announced eight late-breaking science sessions to be presented in Philadelphia from November 10th to November 13th. AHA is focussed on innovation in cardiovascular disease for scientists, clinicians, researchers and other healthcare professionals. Among the event’s highlights are eight late-breaking trial sessions, as listed below. Watch our coverage of… View more
Author(s): Sergio Fazio Added: 3 years ago
Current Indications for Statin and Fibrate Therapy The evidence of cardiovascular protection afforded by statins has recently extended beyond patients with hypercholesterolemia. With the publication of several trials,1-7 bold extrapolations of the power of statin therapy in cardiovascular prevention have been offered: statins equally reduce risk in subjects with or without… View more

Prevention & Chronic Conditions
Author(s): Leo Buckley , Ahmed Aldemerdash Added: 3 years ago
Cardiovascular disease is the leading cause of death in the US.1,2 Although advances in the prevention and treatment of cardiovascular disease have contributed to a decline in mortality rates, this favorable trend has slowed over the past several years.3 Recently, however, a revival of cardiovascular drug development has introduced new treatment options to the market, with several promising… View more

Prevention & Chronic Conditions
Author(s): Kilmer S McCully Added: 3 years ago
Discovery of the Homocysteine Theory of Arteriosclerosis The American biochemist Vincent DuVigneaud discovered a new amino acid in 1932 by treating methionine with sulfuric acid. The structure of this amino acid is similar to cysteine, except for one extra carbon atom, hence the name homocysteine. Subsequent investigation established the role of homocysteine as an intermediate in sulfur amino… View more

Prevention & Chronic Conditions
Author(s): Jakub Podolec , Lukasz Niewiara Added: 3 years ago
Atherosclerosis is the primary cause of coronary artery disease morbidity and mortality worldwide.1 Low-density lipoprotein cholesterol (LDL-C)- lowering therapies have already become one of the most important in the prevention of atherosclerosis complications.2 Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) and thus significantly… View more

Prevention & Chronic Conditions
Author(s): Barbara J Turner , Tara Lagu Added: 3 years ago
Ischemic heart disease and stroke account for nearly 25% of all deaths worldwide.1 With an increasing array of effective medications for hypertension and hyperlipidemia, the toll exacted by vascular disease should diminish. However, control of these two primary causes of vascular disease has been seriously compromised by under-diagnosis and under-treatment.2,3 National survey data in the US has… View more

Prevention & Chronic Conditions
Current Strategies in the Management of Aortic Stenosis
Author(s): Anne H Tavenier , Johny Nicolas , Roxana Mehran Added: 1 year ago

Intervention